Policy Indications: How Materials Science Helps Contain Contain Covid-19 Spread  |  National Edu News: IIT Hyderabad and PharmCADD signed a pact for the co-development of new drugs   |  Teacher Insights: Be Game  |  Health Monitor: Understanding ‘Haemorrhage'  |  National Edu News: Pallikkutam GlobalConnect#3 on 'Innovative Tools for Effective Teaching'  |  Expert Counsel: The Nine Dash Line  |  National Edu News: Astronomers Find One Group of Appearing and Disappearing Stars  |  Teacher Insights: Bird Book for Children to Love Nature  |  International Edu News: New Model to Fight Social Media Deep Fakes  |  Teacher Insights: Universal Lunch Makes Students Healthier  |  Teacher Insights: Physical Activity Boosts Self Regulation  |  Parent Interventions: Anti-Inflammatory Foods Reduce Blood Fats  |  Parent Interventions: New Technique to Treat ADHD  |  Parent Interventions: Reduce Lab Tests in NICU Patients  |  Parent Interventions: Switch Off  |  
January 11, 2021 Monday 03:39:07 PM IST

Scientists discover a natural liver-accumulating drug delivery vehicle

International Edu News

Extracellular vesicles (EVs) are superb potential vectors for the delivery of therapeutic drugs with their low immunogenicity and cytotoxicity. However, issues with biological safety and disease targeting substantially limit their clinical application. EVs from red blood cells (RBC-EVs) are a potential drug delivery vehicle, given their high production and beneficial characteristics in biosafety. The research team led by Prof. CAI Zhijian from Zhejiang University School of Basic Medical Sciences carried out relevant research. Their findings demonstrated that EVs, including RBC-EVs, show natural liver accumulation. Mechanistically, the liver environment induces macrophages to phagocytize RBC-EVs in a C1q-dependent manner. RBC-EVs loaded with antisense oligonucleotides of microRNA-155 showed macrophage-dependent protective effects against acute liver failure (ALF) in a mouse model. These RBC-EVs were also effective in treating ALF.

”As compared with routine doses of doxorubicin and sorafenib (SRF), RBC-EVs loaded with doxorubicin or SRF showed enhanced therapeutic effects on a murine model of orthotopic liver cancer through a mechanism dependent on macrophages,” said Prof. CAI Zhijian. “Importantly, drug-loaded RBC-EVs showed no systemic toxicity at therapeutically effective doses, whereas routine doses of doxorubicin and SRF exhibited obvious toxicity.”